Checkpoint Therapeutics Inc Cash Flow Conversion Efficiency
Checkpoint Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Checkpoint Therapeutics Inc (CKPT) has a cash flow conversion efficiency ratio of -0.717x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-11.69 Million) by net assets ($16.30 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Checkpoint Therapeutics Inc (2015–2024)
Cash flow conversion efficiency of Checkpoint Therapeutics Inc from 2015 to 2024. This chart illustrates how Checkpoint Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Checkpoint Therapeutics Inc for real-time trading data and today's change.
Checkpoint Therapeutics Inc Cash Flow Conversion Ratio Explained
Checkpoint Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Checkpoint Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Checkpoint Therapeutics Inc ranked by their cash flow conversion efficiency. Also see how much is Checkpoint Therapeutics Inc worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dynasty Ceramic Public Company Limited
BK:DCC
|
0.037x |
|
Hunan Huasheng Co Ltd
SHG:600156
|
0.086x |
|
Muang Thai Insurance Public Company Limited
BK:MTI
|
0.031x |
|
Van de Velde NV
BR:VAN
|
0.127x |
|
China Bicycle Co Holdings Ltd
SHE:000017
|
-0.041x |
|
RattanIndia Power Limited
NSE:RTNPOWER
|
0.081x |
|
Earth-Panda Advanced Magnetic Material Co Ltd
SHG:688077
|
0.006x |
|
Shenzhen Glory Medical Co Ltd
SHE:002551
|
0.046x |
Annual Cash Flow Conversion Efficiency for Checkpoint Therapeutics Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of Checkpoint Therapeutics Inc from 2015 to 2024. Review CKPT free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-12.62 Million | $-31.10 Million | 2.463x | -32.46% |
| 2023-12-31 | $-13.05 Million | $-47.59 Million | 3.648x | +23.48% |
| 2022-12-31 | $-19.48 Million | $-57.55 Million | 2.954x | +434.04% |
| 2021-12-31 | $29.75 Million | $-26.31 Million | -0.884x | -89.04% |
| 2020-12-31 | $35.38 Million | $-16.55 Million | -0.468x | +58.75% |
| 2019-12-31 | $18.85 Million | $-21.37 Million | -1.134x | +48.12% |
| 2018-12-31 | $11.81 Million | $-25.80 Million | -2.186x | -112.64% |
| 2017-12-31 | $15.04 Million | $-15.46 Million | -1.028x | -233.74% |
| 2016-12-31 | $32.30 Million | $-9.95 Million | -0.308x | -1189.72% |
| 2015-12-31 | $46.40 Million | $-1.11 Million | -0.024x | -- |
About Checkpoint Therapeutics Inc
Checkpoint Therapeutics, Inc., a commercial -stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is UNLOXCYT, which is in Phase 1 clinical trial to treat patients with selected recurrent or m… Read more